Global Leukemia Academy
Webinar on Recent Updates in Pediatric and AYA ALL: Focus on Asia Pacific Region
Overview
This webinar, targeting the Asia Pacific Region, focused on recent updates in pediatric and AYA ALL, including information from ASH 2019, ASCO 2020, EHA 2020, and EBMT 2020, as well as recent publications.
Experts shared their insights on enactment of new paradigms, including administration of new treatments such as bispecifics, and patient monitoring and management. They also discussed strategic implementation of minimal residual disease (MRD) monitoring.
Date and Location
Thursday, 12 November 2020
7.00 PM – 8.20 PM China Standard Time (CST)
8.00 PM – 9.20 PM Korea Standard Time/Japan Standard Time (KST/JST)
Virtual Meeting
Meeting Content
View the slides and watch the video of the webinar on Recent Updates in Pediatric and AYA ALL: Focus on Asia Pacific Region
Ask your questions directly to the experts and receive their personal insights on current and novel treatment approaches for pediatric and adult patients with acute leukemias.
Faculty
Patrick A. Brown, MD
Johns Hopkins University
School of Medicine, USA
Franco Locatelli, MD, PhD
University of Rome
IRCCS Ospedale Pediatrico
Bambino Gesù, Italy
Hyoung Jin Kang, MD
Seoul National University College
of Medicine
Seoul, Korea
|
Agenda |
This meeting was a 1 hour and 20-minute virtual event. |
| Time | Topic | Presenter | |
| 7.00 PM – 7.05 PM CST 8.00 PM – 8.05 PM KST/JST (5 minutes) |
Welcome and Introductions | Hyoung Jin Kang, MD | |
| 7.05 PM – 7.20 PM CST 8.05 PM – 8.20 PM KST/JST (15 minutes) |
Current Paradigm and Long-Term Toxicities for Pediatric/AYA ALL • Integration of innovative immunotherapies • Role of MRD in treatment • Long-term toxicities |
Franco Locatelli, MD, PhD | |
| 7.20 PM – 7.40 PM CST 8.20 PM – 8.40 PM KST/JST (20 minutes) |
Bispecifics for Pediatric/AYA ALL • Review of trial results in pediatric/AYA ALL • Role of MRD in research and treatment • AYA considerations |
Patrick Brown, MD | |
| 7.40 PM – 7.55 PM CST 8.40 PM – 8.55 PM KST/JST (15 minutes) |
CAR T Cells for Pediatric/AYA ALL • Benefits and risks of CAR Ts and bispecifics • Role of MRD in research and treatment • AYA considerations |
Franco Locatelli, MD, PhD | |
| 7.55 PM – 8.20 PM CST 8.55 PM – 9.20 PM KST/JST (25 minutes) |
Questions to Experts | Hyoung Jin Kang, MD |
